Relay Therapeutics Dirección
Dirección controles de criterios 2/4
El CEO de Relay Therapeutics' es Sanjiv Patel , nombrado en Mar 2017, tiene una permanencia de 7.08 años. compensación anual total es $8.12M, compuesta por 7.9% salario y 92.1% primas, incluidas acciones y opciones de la empresa. posee directamente un 1.04% de las acciones de la empresa, por valor de $8.11M. La antigüedad media del equipo directivo y de la junta directiva es de 6 años y 4.7 años, respectivamente.
Información clave
Sanjiv Patel
Chief Executive Officer (CEO)
US$19.8m
Compensación total
| Porcentaje del salario del CEO | 3.4% |
| Permanencia del CEO | 7.2yrs |
| Participación del CEO | 1.0% |
| Permanencia media de la dirección | 6.1yrs |
| Promedio de permanencia en la Junta Directiva | 4.8yrs |
Actualizaciones recientes de la dirección
Recent updates
Relay Therapeutics, Inc. (NASDAQ:RLAY) Analysts Just Trimmed Their Revenue Forecasts By 12%
Apr 17
Relay Therapeutics: Platform More Important Than Programs
Mar 13Relay Therapeutics: Tapping Into An Unmet Need At A High Price Tag
Feb 13Analyst Forecasts Just Became More Bearish On Relay Therapeutics, Inc. (NASDAQ:RLAY)
Jan 21We Think Relay Therapeutics (NASDAQ:RLAY) Can Afford To Drive Business Growth
Nov 14Will Relay Therapeutics (NASDAQ:RLAY) Spend Its Cash Wisely?
Jun 08Is Relay Therapeutics (NASDAQ:RLAY) In A Good Position To Invest In Growth?
Feb 22Is Relay Therapeutics (NASDAQ:RLAY) In A Good Position To Invest In Growth?
Oct 23Relay set to Equal Weight at Barclays; says fairly valued ahead of catalysts
Sep 30Relay Therapeutics: Bile Duct Cancer Approval Shot Validates Pricey Platform
Sep 18Why did Relay Therapeutics stock drop today?
Sep 09Estimating The Fair Value Of Relay Therapeutics, Inc. (NASDAQ:RLAY)
Jan 02Relay Therapeutics, Inc. (NASDAQ:RLAY) Analysts Are Reducing Their Forecasts For This Year
Aug 17Relay Therapeutics, Inc. (NASDAQ:RLAY) Just Released Its First-Quarter Results And Analysts Are Updating Their Estimates
May 16Relay Therapeutics (NASDAQ:RLAY) Is In A Strong Position To Grow Its Business
Mar 26Read This Before Selling Relay Therapeutics, Inc. (NASDAQ:RLAY) Shares
Feb 01
Relay Therapeutics inks deal for RLY-1971 with Genentech
Dec 14Relay Therapeutics (NASDAQ:RLAY) Is In A Strong Position To Grow Its Business
Dec 08Relay Therapeutics reports Q3 results
Nov 12Análisis de compensación del CEO
| Fecha | Compensación total | Salario | Ingresos de la empresa |
|---|---|---|---|
| Dec 31 2023 | US$20m | US$674k | -US$342m |
| Sep 30 2023 | n/a | n/a | -US$326m |
| Jun 30 2023 | n/a | n/a | -US$344m |
| Mar 31 2023 | n/a | n/a | -US$323m |
| Dec 31 2022 | US$8m | US$642k | -US$291m |
| Sep 30 2022 | n/a | n/a | -US$290m |
| Jun 30 2022 | n/a | n/a | -US$267m |
| Mar 31 2022 | n/a | n/a | -US$384m |
| Dec 31 2021 | US$9m | US$603k | -US$364m |
| Sep 30 2021 | n/a | n/a | -US$261m |
| Jun 30 2021 | n/a | n/a | -US$414m |
| Mar 31 2021 | n/a | n/a | -US$247m |
| Dec 31 2020 | US$4m | US$585k | -US$230m |
| Sep 30 2020 | n/a | n/a | -US$289m |
| Jun 30 2020 | n/a | n/a | -US$95m |
| Mar 31 2020 | n/a | n/a | -US$86m |
| Dec 31 2019 | US$4m | US$585k | -US$75m |
Compensación vs. Mercado: La compensación total de Sanjiv($USD8.12M) está por encima de la media de empresas de tamaño similar en el mercado US ($USD3.47M).
Compensación vs. Ingresos: La compensación de Sanjiv ha aumentado mientras la empresa no es rentable.
CEO
Sanjiv Patel (49 yo)
7.2yrs
Permanencia
US$19,770,838
Compensación
Dr. Sanjiv K. Patel, M.A., M.D., M.B.A., MBBS, had been an Independent Director at Prothena Corporation plc since May 18, 2021 until July 1, 2023. He serves as Independent Director of ARYA Sciences Acquisi...
Equipo directivo
| Nombre | Posición | Permanencia | Compensación | Propiedad |
|---|---|---|---|---|
| Co-Founder & Independent Chairman | 9.1yrs | US$581.14k | 0.18% $ 1.5m | |
| CEO, President & Director | 7.2yrs | US$19.77m | 1.03% $ 8.9m | |
| Co-Founder & Director | no data | US$548.64k | 0.75% $ 6.5m | |
| Chief Financial Officer | 6.1yrs | US$5.22m | 0.023% $ 194.7k | |
| Chief Legal Officer & Secretary | 6.2yrs | US$4.51m | 0.023% $ 199.3k | |
| Chief Corporate Development Officer | no data | US$6.78m | 0.033% $ 285.8k | |
| President of Research & Development | 6.1yrs | US$8.57m | 0.037% $ 316.5k | |
| Vice President of Corporate Development & Strategy | 6.8yrs | sin datos | sin datos | |
| Chief Scientific Officer of Late Research | no data | sin datos | sin datos | |
| Chief Medical Officer & Head of Precision Medicine | 4.5yrs | sin datos | sin datos | |
| Chief Pharmaceutical Development Officer | 5.4yrs | sin datos | sin datos | |
| Chief Scientific Officer of Early Research | no data | sin datos | sin datos |
6.1yrs
Permanencia media
50yo
Promedio de edad
Equipo directivo experimentado: El equipo directivo de RLAY es experimentado (6 años antigüedad media).
Miembros de la Junta
| Nombre | Posición | Permanencia | Compensación | Propiedad |
|---|---|---|---|---|
| Co-Founder & Independent Chairman | 9.1yrs | US$581.14k | 0.18% $ 1.5m | |
| CEO, President & Director | 7.2yrs | US$19.77m | 1.03% $ 8.9m | |
| Co-Founder & Director | 7.8yrs | US$548.64k | 0.75% $ 6.5m | |
| Independent Director | 4.9yrs | US$548.64k | 0.019% $ 163.0k | |
| Independent Director | 5.6yrs | US$551.14k | 0% $ 0 | |
| Member of Oncology Advisory Board | 4.2yrs | sin datos | sin datos | |
| Independent Director | 7.2yrs | US$551.14k | 0.030% $ 260.8k | |
| Member of Oncology Advisory Board | 4.2yrs | sin datos | sin datos | |
| Independent Director | 4.6yrs | US$558.64k | 0.019% $ 163.0k | |
| Member of Oncology Advisory Board | 4.2yrs | sin datos | sin datos | |
| Member of Oncology Advisory Board | 4.2yrs | sin datos | sin datos | |
| Member of Oncology Advisory Board | 4.2yrs | sin datos | sin datos |
4.8yrs
Permanencia media
61.5yo
Promedio de edad
Junta con experiencia: La junta directiva de RLAY se considera experimentada (4.7 años de antigüedad promedio).